Video Buzz v1

RelatedLinks

May 28th

• Cancer drug wiped patient's fingerprints - ABC News (Australian Broadcasting Corporation): A patient who took an anti-cancer drug lost his fingerprints, which caused him to be detained for hours when he tried to visit the United States.

May 27th

• Travel warning with capecitabine -- Annals of Oncology: Cancer drug causes patient to lose fingerprints and be detained by US immigration...
• Capecitabine - Wikipedia, the free encyclopedia
• BBC NEWS | Health | Cancer drug erases fingerprints
• Cancer drug erases fingerprints: Interesting adverse effect, but only when combined with US immigration

May 15th

• NEJM -- Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer: capecitabine

May 8th

• Ixabepilone in Metastatic Breast Cancer: An editorial accompanying a new cost-efficacy study in the same issue of the journal found that the addition of ixabepilone to capecitabine (Xeloda) adds about $31,000 to the overall medical costs of metastatic breast cancer while providing about 1 more month of "quality- adjusted" survival.

December 21st

• Metastatic Breast Cancer Patients With Poor Performance Status Respond Well to Ixabepilone Plus Capecitabine: Presented at SABCS: For patients with metastatic breast cancer who have poor performance status and who show resistance to anthracyclines and taxanes, ixabepilone plus capecitabine improves overall survival, progression-fr ee survival, and tumor response compared with capecitabine alone, according to results of 2 large phase 3 studies, presented at the 31st Annual San Antonio Breast Cancer Symposium (SABCS).

December 9th

• Competitor - Ixempra - Pfizer - against breast cancer tumors resistant or refractory to anthracyclines , taxanes, and capecitabine: IXEMPRA is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicate d. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting.

January 2nd

• NEJM -- Capecitabine and Oxaliplatin for Advanced Esophagogastri c Cancer

November 26th

• Xeloda (kapesitabiini ) 150 mg kalvopäällyste iset tabletit - Lääkeinfo.fi - Valmisteen mukaan: Xeloda 150 mg kalvopäällyste iset tabletit kapesitabiini
• OralChemo.org - oral cyclophosphami de: Oral cyclophosphami de has been used since the early 1970s in combination with methotrexate and fluorouracil/5 -FU for the treatment of breast cancer that has spread. It is also used in this combination as adjuvant therapy following surgery, where it improv

RelatedImages

No Images Available!

Video Buzz > Capecitabine

Video Buzz Video Player :)

No Matching Video

No video for Capecitabine is available at this time.

Related Capecitabine News

Capecitabine Podcasts

Do you prefer to listen to your capecitabine gossip? Check out Podzy Podcast Directory > Capecitabine.

Capecitabine Products

Looking for capecitabine related products, then look no further. Try our new Capecitabine Shop.